Imagen de Portada

Hirschsprung's disease. Management

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Claudio Morera, Samuel Nurko
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population
por: Antonio De Vincentis, et al.
Publicado: (2024)

Inflammatory bowel disease in 2024 and beyond
por: Richard B. Gearry, et al.
Publicado: (2024)

Review article: Oesophageal disorders in chronic liver disease
por: Francisco Idalsoaga, et al.
Publicado: (2024)

Review article: Prevention of inflammatory bowel disease—The path forward
por: Sérgio Bronze, et al.
Publicado: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
por: Yaomin Wang, et al.
Publicado: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
por: Carolin V. Schneider, et al.
Publicado: (2024)

UK guideline on the transition and management of childhood liver diseases in adulthood
por: Deepak Joshi, et al.
Publicado: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
por: Zhuo Li, et al.
Publicado: (2024)

Performance of bowel preparation quality scales in patients with Crohn's disease
por: Virginia Solitano, et al.
Publicado: (2024)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
por: Pojsakorn Danpanichkul, et al.
Publicado: (2024)

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras
por: Daniel Tassone, et al.
Publicado: (2024)

Editorial: GLP‐1 receptor agonists in inflammatory bowel disease—Is it time?
por: Konstantinos Arvanitakis, et al.
Publicado: (2024)

Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
por: Nurulamin M. Noor, et al.
Publicado: (2024)

Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
por: Tsz Hong Yiu, et al.
Publicado: (2024)

Review article: Evidence‐based dietary management of inflammatory bowel disease
por: Peter R. Gibson, et al.
Publicado: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
por: Parminder Kaur, et al.
Publicado: (2024)

Letter: The use of large language models as medical chatbots in digestive diseases
por: Hinpetch Daungsupawong, et al.
Publicado: (2024)

Editorial: Treatments for inflammatory bowel disease across the age‐spectrum—Are they the same?
por: Agnes Hiu Yan Ho, et al.
Publicado: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood
por: Paul Henderson
Publicado: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
por: Abhinav Vasudevan, et al.
Publicado: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
por: Chen‐Pi Li, et al.
Publicado: (2024)

Systematic review: The use of large language models as medical chatbots in digestive diseases
por: Mauro Giuffrè, et al.
Publicado: (2024)

Letter: Allostatic load—A potential key in the development of inflammatory bowel disease
por: Maryam Kharal, et al.
Publicado: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
por: Richie Manikat, et al.
Publicado: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
por: Ivan Arcari, et al.
Publicado: (2024)

Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease
por: Jianhui Zhao, et al.
Publicado: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
por: Nina Dominik, et al.
Publicado: (2024)

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
por: Abhinav Vasudevan, et al.
Publicado: (2024)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
por: Maria Ling Lundström, et al.
Publicado: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
por: Abdel‐Aziz Shaheen, et al.
Publicado: (2024)

Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease
por: Finlay Macrae
Publicado: (2025)

Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
por: Uma Mahadevan, et al.
Publicado: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
por: Thanawin Pramotedham, et al.
Publicado: (2026)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
por: Amanda Ricciuto, et al.
Publicado: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply
por: Mikkel Malham, et al.
Publicado: (2024)

Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
por: Thanaboon Chaemsupaphan, et al.
Publicado: (2024)

Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
por: Léa Sequier, et al.
Publicado: (2024)

Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
por: Donghee Kim, et al.
Publicado: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
por: Sung Won Chung, et al.
Publicado: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
por: Jannis Kountouras, et al.
Publicado: (2024)